Thermo Fisher Scientific announced on April 2, 2026 the launch of the Gibco CTS Compleo Fill and Finish System, an automated, functionally closed solution designed to streamline formulation and filling in cell‑therapy manufacturing.
The new platform addresses the variability inherent in patient‑derived cell products by reducing manual handling and contamination risk. By integrating key steps into a single workflow, the system promises greater consistency and throughput for cell‑therapy production lines.
The cell and gene therapy manufacturing market is expanding rapidly. Projections estimate growth from USD 19.3 billion in 2024 to an estimated USD 146.2 billion by 2032, a CAGR of 28.8 %. Another forecast projects the market to reach USD 18.89 billion by 2034, growing at 14.6 % annually. These figures underscore the strong demand for scalable, compliant manufacturing solutions such as the Compleo system.
Thermo Fisher’s financial performance provides context for the launch. In Q4 2025 the company generated $12.21 billion in revenue, up 7 % YoY, and reported adjusted EPS of $6.57, beating consensus estimates. Full‑year 2025 revenue totaled $44.56 billion, a 4 % increase from 2024, with the Life Sciences Solutions segment showing a recovery trend. The new system adds a high‑growth revenue stream that complements the company’s broader strategy of delivering end‑to‑end biopharma services.
Other industry players also offer automated fill‑finish solutions for cell therapies, but Thermo Fisher’s integration of the Gibco brand and its existing Life Sciences Solutions portfolio gives it a competitive advantage in a market that is rapidly moving toward commercial manufacturing.
Marc N. Casper, chairman, president, and CEO, highlighted the company’s strong finish to 2025, noting that “our team leveraged the PPI Business System to drive operational excellence and enable our customers’ success.” The launch aligns with Thermo Fisher’s focus on scalable, compliant cell‑therapy production and reinforces its one‑stop‑shop model.
The Compleo Fill and Finish System positions Thermo Fisher to capture growing demand in the cell‑therapy manufacturing sector, supports its end‑to‑end biopharma services, and adds a new revenue stream in a high‑growth market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.